Analyst Conference Summaries

Biotechnology Investor Aids

Dicerna Pharmaceuticals

conference date: November 9, 2021 @ 5:30 AM Pacific Time

Dicerna to be Acquired by Novo Nordisk

Dicerna Pharmaceuticals May Be the Best Value Among RNAi Companies [September 15, 2020 at Seeking Alpha]

Dicerna: An RNA Therapy-Based 21st Century Likely Winner [July 12, 2019 at Seeking Alpha]

Dicerna (DRNA)
Q1 2021
Dicerna (DRNA)
Q2 2021
Dicerna (DRNA)
Q3 2021
May 6, 2021 Aug. 9, 2021 Nov. 9, 2021  
Dicerna (DRNA)
Q1 2020
Dicerna (DRNA)
Q2 2020
Dicerna (DRNA)
Q3 2020
Dicerna (DRNA)
Q4 2020
May 7, 2020 Aug. 6, 2020 Nov. 5, 2020 Feb. 25, 2021
  Dicerna (DRNA)
Q2 2019
Dicerna (DRNA)
Q3 2019
Dicerna (DRNA)
Q4 2019
  Aug. 8, 2019 Nov. 7, 2019 Feb. 27, 2020

Dicerna Pharmaceuticals (DRNA) is a clinical-stage biotechnology company specializing in RNA therapies for genetic diseases.

Dicerna Pharmaceuticals web site

I bought my first DRNA on September 14, 2020. I sold mine on the acquisition announcement on 11/18/2021



More Analyst Conference Pages:


Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2021 William P. Meyers